GlassScriptPhysician profile
Whei Ying Lim
NPI 1447668942
$4,739.31
in general payments reported to CMS, 2019-2025
28 companies · $1,721 in 2025
The $1,721 reported for 2025 was more than what 75% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $150 · 2021: $192 · 2022: $598 · 2023: $1,116 · 2024: $963 · 2025: $1,721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,520 · Education: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,519.62 |
| Education | $280.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $870.70 | 2021-2025 | |
| Novo Nordisk INC | $597.37 | 2020-2025 | Sogroya, Norditropin |
| Sanofi-Aventis U.S. LLC | $342.44 | 2023-2025 | |
| Tolmar, INC. | $323.82 | 2023-2025 | Fensolvi |
| Beta Bionics, INC. | $300.43 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Xeris Pharmaceuticals, INC. | $298.18 | 2021-2025 | Gvoke Hypopen |
| Neurocrine Biosciences, INC. | $226.18 | 2024-2025 | Crenessity |
| Dexcom, INC. | $216.47 | 2020-2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $163.89 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Pfizer INC. | $153.91 | 2020-2025 | |
| Ascendis Pharma Endocrinology INC | $148.83 | 2022-2025 | Skytrofa |
| Lilly USA, LLC | $145.53 | 2020-2025 | Zepbound |
| Insulet Corporation | $143.64 | 2022-2025 | Omnipod |
| Azurity Pharmaceuticals, INC. | $133.59 | 2023-2025 | Triptodur, Gliadel |
| Alexion Pharmaceuticals, INC. | $95.09 | 2022-2025 | Strensiq |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $87.29 | 2020-2022 | |
| Rhythm Pharmaceuticals, INC. | $82.39 | 2023-2025 | Imcivree, Imcivree |
| Biomarin Pharmaceutical INC. | $80.04 | 2022-2025 | Voxzogo 1.2mg, Vimizim |
| Kyowa Kirin, INC. | $76.51 | 2023-2025 | Crysvita |
| Tolmar Pharmaceuticals, INC. | $67.92 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $37.86 | 2023-2024 | Oxlumo |
| Sequel Med Tech, LLC | $29.02 | 2025 | Twiist |
| Ultragenyx Pharmaceutical INC. | $27.75 | 2023 | |
| Endo USA, INC. | $22.35 | 2025 | Supprelin |
| Medtronic, INC. | $18.10 | 2024 | Minimed 780g |
| Endo Pharmaceuticals INC. | $16.96 | 2021 | |
| Amryt Pharma Holdings LTD | $16.69 | 2020 | |
| Sandoz INC. | $16.36 | 2025 | Omnitrope |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whei Ying Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.